A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia

被引：4

作者：

Parrondo, Ricardo D. ^{[1
]}

Dutta, Navnita ^{[2
]}

Laplant, Betsy R. ^{[3
]}

Elliott, Jamie ^{[1
]}

Fernandez, Andre ^{[1
]}

Zimmerman, Ashley ^{[1
]}

Cicco, Gina ^{[2
]}

Han, Bing ^{[2
]}

Heslop, Keisha ^{[1
]}

Chapin, Dustin ^{[1
]}

Sher, Taimur ^{[1
]}

Roy, Vivek ^{[1
]}

Rasheed, Ahsan ^{[1
]}

Das, Saurav ^{[1
]}

Chanan-Khan, Asher A. ^{[1
,2
]}

Paulus, Aneel ^{[2
]}

Ailawadhi, Sikander ^{[1
,2
,4
]}

机构：

[1] Mayo Clin, Canc Ctr, Jacksonville, FL USA

[2] Mayo Clin, Dept Canc Biol, Jacksonville, FL USA

[3] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA

[4] Mayo Clin, Div Hematol Oncol, 4500 San Pablo Rd, Mangurian Bldg 3rd Floor, Jacksonville, FL 32224 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 05期

关键词：

clinical trials; non Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia; WALDENSTROM MACROGLOBULINEMIA; RITUXIMAB; DEXAMETHASONE; ZANUBRUTINIB; THERAPY;

D O I：

10.1111/bjh.19320

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This phase II study evaluated time-limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenstrom macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow-up time of 25.7 months, the median progression-free survival (PFS) was 22.9 months. While the primary end-point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM.

引用

页码：1825 / 1829

页数：5

共 50 条

[21] Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms [J].

Ravandi, Farhad ;

Aribi, Ahmed ;

O'Brien, Susan ;

Faderl, Stefan ;

Jones, Dan ;

Ferrajoli, Alessandra ;

Huang, Xuelin ;

York, Sergernne ;

Pierce, Sherry ;

Wierda, William ;

Kontoyiannis, Dimitrios ;

Verstovsek, Srdan ;

Pro, Barbara ;

Fayad, Luis ;

Keating, Michael ;

Kantarjian, Hagop .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) :5425-5430

[22] A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients [J].

Byun, Ja Min ;

Shin, Junghoon ;

Kim, Sang-A ;

Park, Hyunkyung ;

Lee, Jiyun ;

Shin, Dong-Yeop ;

Hong, Junshik ;

Lee, Jeong-Ok ;

Bang, Soo-Mee ;

Kim, Inho ;

Yoon, Sung-Soon ;

Koh, Youngil .

CANCER RESEARCH AND TREATMENT, 2024, 56 (02) :675-680

[23] A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia [J].

Tam, Constantine S. ;

LeBlond, Veronique ;

Novotny, William ;

Owen, Roger G. ;

Tedeschi, Alessandra ;

Atwal, Siminder ;

Cohen, Aileen ;

Huang, Jane ;

Buske, Christian .

FUTURE ONCOLOGY, 2018, 14 (22) :2229-2237

[24] All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study [J].

Touzeau, Cyrille ;

Perrot, Aurore ;

Roussel, Murielle ;

Karlin, Lionel ;

Benboubker, Lotfi ;

Jacquet, Caroline ;

Mohty, Mohamad ;

Facon, Thierry ;

Manier, Salomon ;

Chretien, Marie-Lorraine ;

Tiab, Mourad ;

Hulin, Cyrille ;

Leleu, Xavier ;

Loiseau, Herve Avet ;

Dejoie, Thomas ;

Planche, Lucie ;

Attal, Michel ;

Moreau, Philippe .

HAEMATOLOGICA, 2022, 107 (07) :1693-1697

[25] Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study [J].

Tanaka, Maki ;

Takamatsu, Yasushi ;

Anan, Keisei ;

Ohno, Shinji ;

Nishimura, Reiki ;

Yamamoto, Yutaka ;

Masuda, Norikazu ;

Mitsuyama, Shoshu ;

Tamura, Kazuo .

ANTI-CANCER DRUGS, 2010, 21 (04) :453-458

[26] A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy [J].

Finazzi, Guido ;

Vannucchi, Alessandro M. ;

Martinelli, Vincenzo ;

Ruggeri, Marco ;

Nobile, Francesco ;

Specchia, Giorgina ;

Pogliani, Enrico Maria ;

Olimpieri, Odoardo Maria ;

Fioritoni, Giuseppe ;

Musolino, Caterina ;

Cilloni, Daniela ;

Sivera, Piera ;

Barosi, Giovanni ;

Finazzi, Maria Chiara ;

Di Tollo, Silvia ;

Demuth, Tim ;

Barbui, Tiziano ;

Rambaldi, Alessandro .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) :688-694

[27] A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases [J].

Leone, Jose Pablo ;

Duda, Dan G. ;

Hu, Jiani ;

Barry, William T. ;

Trippa, Lorenzo ;

Gerstner, Elizabeth R. ;

Jain, Rakesh K. ;

Tan, Sally ;

Lawler, Elizabeth ;

Winer, Eric P. ;

Lin, Nancy U. ;

Tolaney, Sara M. .

BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) :113-123

[28] Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma [J].

Berdeja, Jesus G. ;

Hart, Lowell L. ;

Mace, Joseph R. ;

Arrowsmith, Edward R. ;

Essell, James H. ;

Owera, Rami S. ;

Hainsworth, John D. ;

Flinn, Ian W. .

HAEMATOLOGICA, 2015, 100 (05) :670-676

[29] A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients [J].

Laquente, Berta ;

Lopez-Martin, Jose ;

Richards, Donald ;

Illerhaus, Gerald ;

Chang, David Z. ;

Kim, George ;

Stella, Philip ;

Richel, Dirk ;

Szcylik, Cezary ;

Cascinu, Stefano ;

Frassineti, G. L. ;

Ciuleanu, Tudor ;

Hurt, Karla ;

Hynes, Scott ;

Lin, Ji ;

Lin, Aimee Bence ;

Von Hoff, Daniel ;

Calvo, Emiliano .

BMC CANCER, 2017, 17

[30] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study [J].

Tempero, M. ;

Oh, D-Y ;

Tabernero, J. ;

Reni, M. ;

Van Cutsem, E. ;

Hendifar, A. ;

Waldschmidt, D-T ;

Starling, N. ;

Bachet, J-B ;

Chang, H-M ;

Maurel, J. ;

Garcia-Carbonero, R. ;

Lonardi, S. ;

Coussens, L. M. ;

Fong, L. ;

Tsao, L. C. ;

Cole, G., Jr. ;

James, D. ;

Macarulla, T. .

ANNALS OF ONCOLOGY, 2021, 32 (05) :600-608

← 1 2 3 4 5 →